Overview

This trial is active, not recruiting.

Condition buttock ptosis
Treatment ulthera treatment
Sponsor Ulthera, Inc
Start date September 2014
End date July 2016
Trial size 24 participants
Trial identifier NCT02270892, ULT-142

Summary

Up to 24 subjects will be enrolled and treated. Enrolled subjects will receive two Ulthera® treatments, 90 days apart. Follow-up visits will occur at 90, 180, and 270 days following the last treatment. Study images will be obtained pre-treatment, immediately post-treatment, and at each follow-up visit.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation randomized
Endpoint classification safety/efficacy study
Intervention model parallel assignment
Masking single blind (outcomes assessor)
Primary purpose treatment
Arm
(Active Comparator)
Left side Ulthera treatment
ulthera treatment Ultherapy, Ulthera System Treatment
Focused ultrasound energy delivered below the surface of the skin
(Active Comparator)
Right side Ulthera treatment
ulthera treatment Ultherapy, Ulthera System Treatment
Focused ultrasound energy delivered below the surface of the skin

Primary Outcomes

Measure
90-day quantitative buttock lift
time frame: 90 days following last treatment
180-day quantitative buttock lift
time frame: 180 days following last treatment
270-day quantitative buttock lift
time frame: 270 days following last treatment

Secondary Outcomes

Measure
90-day qualitative improvement in buttock ptosis
time frame: 90 days following last treatment
180-day qualitative improvement in buttock ptosis
time frame: 180 days following last treatment
270-day qualitative improvement in buttock ptosis
time frame: 270 days following last treatment
90-day Clinician Buttock Improvement Scale (CBIS)
time frame: 90 days following last treatment
180-day Clinician Buttock Improvement Scale (CBIS)
time frame: 180 days following last treatment
270-day Clinician Buttock Improvement Scale (CBIS)
time frame: 270 days following last treatment
90-day Subject Buttock Improvement Scale (SBIS)
time frame: 90 days following last treatment
180-day Subject Buttock Improvement Scale (SBIS)
time frame: 180 days following last treatment
270-day Subject Buttock Improvement Scale (SBIS)
time frame: 270 days following last treatment
90-day Patient Satisfaction Questionnaire (PSQ)
time frame: 90 days following last treatment
180-day Patient Satisfaction Questionnaire (PSQ)
time frame: 180 days following last treatment
270-day Patient Satisfaction Questionnaire (PSQ)
time frame: 270 days following last treatment
Balancing treatment 90-day Patient Satisfaction Questionnaire (PSQ)
time frame: 90 days following last balancing treatment
Balancing treatment 90-day Subject Buttock Improvement Scale (SBIS)
time frame: 90 days following last balancing treatment
Balancing treatment 90-day Clinician Buttock Improvement Scale (CBIS)
time frame: 90 days following last balancing treatment
Balancing treatment 90-day quantitative buttock lift
time frame: 90 days following last balancing treatment

Eligibility Criteria

Female participants from 18 years up to 65 years old.

Inclusion Criteria: 1. Female, age 18 to 65 years. 2. Subject in good health. 3. Mild to moderate buttock ptosis based on Investigator evaluation. 4. BMI <25. 5. No history of weight gain or loss of greater than 10 pounds within the past year. 6. No planned weight loss or gain for the duration of the study. 7. No pregnancy within the past year. 8. Willingness to refrain from use of aspirin, Ibuprofen, Naproxen or any other NSAID prior to each study treatment and chronic use during the entire post-treatment study period. If a chronic user, a washout period of 4 weeks is required prior to study treatment #1. Washout period for limited acute NSAID use, i.e., a maximum of 2-3 doses, is required in the 2 weeks prior to any study treatment visit. 9. No immunosuppressive therapy, e.g., oral steroid treatment, within the past 4 weeks and during the entire post-treatment study period. Washout period, if recent use, for 4 weeks prior to study treatment #1. 10. Subject must desire improvement of her buttock ptosis as demonstrated by a Dissatisfaction response on a baseline Patient Satisfaction Questionnaire, i.e., Dissatisfied, Neither Satisfied or Dissatisfied, Slightly Satisfied, Satisfied, Very Satisfied. 11. Willingness to refrain from receiving spray tans or using self-tanning lotions from mid-thigh to waist within 2 weeks of any study assessments for the duration of the trial. 12. Willingness to avoid as much as possible, direct and prolonged sun exposure from mid-thigh to waist for the duration of the study. 13. Willingness to refrain from topical steroid use, tretinoin, caffeine cream and other prescription or over-the-counter cellulite reduction topicals to the affected area 2 weeks prior to study treatment #1 and for the duration of the study period. 14. Understands and accepts the obligation not to undergo any other procedures in the areas to be treated through the follow-up period. 15. Willingness and ability to comply with protocol requirements, including returning for follow-up visits and abstaining from exclusionary procedures for the duration of the study. 16. Subjects of childbearing potential must have a negative urine pregnancy test result and must not be lactating at the Baseline Visit and be willing and able to use an acceptable method of birth control (e.g. barrier methods used with a spermicidal agent, hormonal methods, IUD, surgical sterilization, abstinence) during the study. Women will not be considered of childbearing potential if one of the following conditions is documented on the medical history: 1. Postmenopausal for at least 12 months prior to study; 2. Without a uterus and/or both ovaries; or 3. Bilateral tubal ligation at least six months prior to study enrollment. 17. Absence of physical or psychological conditions unacceptable to the investigator. 18. Willingness and ability to provide written consent for study-required photography and adherence to photography procedures. 19. Willingness and ability to provide written informed consent and HIPAA authorization prior to performance of any study-related procedure. Exclusion Criteria: 1. Radiofrequency, CoolSculpting, liposuction, other energy-based treatment in the area to be treated for body contouring, fat reduction, improvement of cellulite, or reduction of buttock ptosis within 1 year prior to study participation or during the study. 2. Short-wave or massage therapy in the area to be treated for treatment of cellulite or buttock ptosis within 3 months prior to study participation or during the study. 3. BMI greater than or equal to 25. 4. Presence of an active systemic or local skin disease that may affect wound healing. 5. Excessive subcutaneous fat in the area to be treated. 6. Excessive skin laxity on the area to be treated. 7. Severe buttock ptosis. 8. Significant scarring or tattoos in the area to be treated that would interfere with assessing results. 9. Open wounds or lesions in the area to be treated. 10. Inability to understand the protocol or to give informed consent. 11. History of chronic drug or alcohol abuse. 12. History of autoimmune disease. 13. Has a known allergy or a known contraindication to ketorolac tromethamine (Toradol). 14. Concurrent therapy that, in the investigator's opinion, would interfere with the evaluation of the safety or efficacy of the study device. 15. Subjects who anticipate the need for inpatient surgery or overnight hospitalization during the study. 16. Subjects who, in the investigator's opinion, have a history of poor cooperation, noncompliance with medical treatment, or unreliability. 17. Concurrent enrollment in any study involving the use of investigational devices or drugs. 18. Current smoker or history of smoking in the last 5 years. 19. Current user of any nicotine-containing products, e.g., e-cigarettes, Nicorette gum, nicotine patches, etc. 20. History of the following cosmetic treatments in the area to be treated: 1. Skin tightening procedure within the past year; 2. Buttock implants; 3. Buttock fillers (e.g., silicone, semi-permanent or permanent fillers or autologous fat injections); 4. Fat emulsifiers; 5. Injections for the treatment of cellulite. 21. History of using the following prescription medications: 1. Accutane or other systemic retinoids within the past 6 months; 2. Topical retinoids, tretinoin, caffeine cream and other prescription or over-the-counter cellulite reduction topicals within the past 2 weeks; 3. Antiplatelet agents/Anticoagulants (Coumadin, Heparin, Plavix); 4. Psychiatric drugs that in the investigators opinion would impair the subject from understanding the protocol requirements or understanding and signing the informed consent.

Additional Information

Official title Evaluation of the Ulthera® System for Lifting of the Buttock
Description This study is a prospective, single-blinded, randomized, split-body clinical study to be conducted at one clinical site. Investigator will assess baseline buttock ptosis to confirm subject eligibility. Enrolled subjects meeting all entrance criteria and who are confirmed to be eligible for study treatment will be randomized/assigned into one of two treatment groups: "Right side treated" and "Left side treated". All subjects will receive two, single-sided, dual-depth Ultherapy® treatments using the 4-4.5mm and 7-3.0mm transducers at 0.90J and 0.30J, respectively. Standardized images will be taken using standard 2D and Vectra 3D digital imaging systems. Subjects completing all study visits will be given the option of receiving two balancing treatments, 90 days apart, and will be required to complete one study visit at 90 days following the last balancing treatment. Quantititative and qualititative assessment of pre- versus post-treatment buttock ptosis will be completed for each post-treatment time point. Subjects will also complete a questionnaire at each study visit.
Trial information was received from ClinicalTrials.gov and was last updated in October 2016.
Information provided to ClinicalTrials.gov by Ulthera, Inc.